Sesen Bion (NASDAQ: SESN) has announced the completion of its marketing planning ahead of the expected Vicineum launch in the US once approved. Equally, the company has progressed to the implementation stage that will focus on executing Vicineum commercial strategy.
FDA reviewing BLA for Vicineum
The FDA is currently reviewing the Biologics License Application for Vicineum, Sesen Bio’s flagship program, for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) treatment in the United States under Priority Review, with a target Prescription Drug User Fee Act (PDUFA) deadline of August 18, 2021.
Sesen Bio’s chief commercial officer, Patricia Drake, said, “We are thrilled to have this experienced commercial team on board at Sesen Bio to build capabilities as we approach the potential commercial launch of Vicineum in the US market. They have made incredible progress across the core functions of sales, marketing and market access. We also believe our network of Urology and Uro-oncology KOL speakers will play an integral role in allowing us to educate their peers about Vicineum, which we believe will be a new tool in their practices to serve a large unmet medical need in NMIBC.”
Sesen Bio has hired personnel to commercialize Vicineum
Already, the company has hired 25 talented employees to provide cross-functional support and 34 of 35 sales agents as part of the contract sales organization that it plans to deploy across four customer-centric areas. The target is around 2,000 high BCG prescribers to drive awareness, pilot, and Vicineum adoption for the treatment. If approved, marketing initiatives will commence right away, and the Vicineum medication will be commercially available to patients and physicians in Q4 2021.
Besides expanding its sales staff, Sesen Bio has identified and begun training 14 key opinion leaders to engage clinicians and educate them about the medication for BCG-unresponsive NMIBC treatment as part of its national speaker programs.